Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Pfizer looks to outpace dimmed expectations in 2Q
01:24pm, Thursday, 27'th Jul 2023
Pfizer Inc (NYSE:PFE) will report earnings before the bell on August 1, but analysts aren't overly optimistic about the pharma company's second quarter earnings. Pfizer is expected to report earning
My International Portfolio: Approaching Another Major Milestone And Looking Into Recent Additions
01:16pm, Thursday, 27'th Jul 2023
I'm your main street neighbor investor in his mid-30s sharing his brokerage account investment journey pursuing a dividend growth strategy. Dividends received YTD totaling $4155 up 18% compared to the
Does Pfizer's Latest Biotech Move Make It a Buy?
09:53am, Thursday, 27'th Jul 2023
Pfizer and Flagship Pioneering will collaborate on a handful of biotech programs. This will seed Pfizer's business development pipeline with opportunities for acquisitions.
2 Dirt Cheap Dividend Stocks to Buy Right Now
09:37am, Thursday, 27'th Jul 2023
Bristol Myers' innovative wheel should keep revenue moving in the right direction. Pfizer's success in the coronavirus market is helping fund other potential products.
2 No-Brainer Cathie Wood Stocks to Buy Right Now
11:15am, Wednesday, 26'th Jul 2023
Cathie Wood is having an exceptional 2023. Vertex Pharmaceuticals and Pfizer are two of Wood's holdings that stand out as top buys right now.
How Pfizer Stands In My Investment Plans For Our Dividend Growth Portfolio
12:18am, Tuesday, 25'th Jul 2023
My top six criteria for measuring dividend safety, and why Pfizer appears to satisfy them. There are no free lunches in the stock market - but there are alternative ways to assess opportunities, trade
Pfizer says supply of some drugs may be disrupted after NC tornado
04:54pm, Monday, 24'th Jul 2023
Drugmaker Pfizer Inc said over 30 drugs, including injections of painkiller fentanyl and anesthetic lidocaine, may see supply disruption after a tornado destroyed a warehouse at its Rocky Mount, North
Pfizer (PFE) to Report Q2 Earnings: Here's What to Expect
01:05pm, Monday, 24'th Jul 2023
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.
Tornado damage to North Carolina Pfizer plant unlikely to cause significant drug supply impacts, FDA says
01:20pm, Saturday, 22'nd Jul 2023
FDA Commissioner Robert Califf said that his agency does not expect immediate significant impacts on supply after a tornado ripped through a North Carolina Pfizer plant this week.
Tornado Damages Pfizer Plant In North Carolina, Conspiracy Theories Swirl
10:09pm, Friday, 21'st Jul 2023
Since this facility produces around 25% of Pfizer's sterile injectable products for U.S. hospitals, this may mean yet more product shortages in this country.
Pfizer to end license deal with Syros for blood disorder therapies
05:46pm, Friday, 21'st Jul 2023
Syros Pharmaceuticals said on Friday Pfizer will terminate a license deal between the companies related to the development of novel therapies for two blood disorders.
Pfizer says no major tornado damage to drug manufacturing areas of North Carolina facility
05:05pm, Friday, 21'st Jul 2023
The pharmaceutical company did not say whether it expected the tornado damage to lead to new drug shortages for sterile injectables.
Pfizer says most tornado damage to Rocky Mount facility was in warehouse
03:15pm, Friday, 21'st Jul 2023
Pfizer Inc. PFE, +1.55% said Friday that most of the damage from Wednesday's tornado that ripped through its Rocky Mount, N.C., manufacturing facility was to the warehouse, which stores raw materials,
Pfizer's production facilities appear undamaged in N. Carolina tornado, CEO says
02:41pm, Friday, 21'st Jul 2023
Pfizer CEO Albert Bourla said on Friday that hurricane damage this week had almost completely destroyed the drugmaker's plant in Rocky Mount, North Carolina, but that production facilities do not seem
EU health regulator backs Pfizer's RSV vaccine for infants, older adults
08:12am, Friday, 21'st Jul 2023
The European Union's health regulator on Friday backed authorization of Pfizer's vaccine for respiratory syncytial virus (RSV) for use in infants up to 6 months of age and older adults.
